Clinical Trials Logo

Pancreatic Cancer Metastatic clinical trials

View clinical trials related to Pancreatic Cancer Metastatic.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04852367 Withdrawn - Clinical trials for Pancreatic Ductal Adenocarcinoma

PanDox: Targeted Doxorubicin in Pancreatic Tumours

PanDox
Start date: June 16, 2021
Phase: Phase 1
Study type: Interventional

This study will combine focused ultrasound to generate heat, and a heat-sensitive chemotherapy drug (ThermoDox®), delivered into the blood of participants with non-resectable pancreatic cancer. We will compare this to standard delivery of chemotherapy - the drug Doxorubicin given into the blood without the addition of ultrasound. We aim to determine whether the novel approach to delivering chemotherapy with heating the tumour by focused ultrasound can enhance the amount of drug delivered to pancreatic tumours. This will be measured by analysing a biopsy sample of treated tumour.

NCT ID: NCT04799431 Withdrawn - Clinical trials for Colorectal Cancer Metastatic

Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer

Start date: May 3, 2023
Phase: Phase 1
Study type: Interventional

Phase 1 study evaluating feasibility, safety, and immune response to a personalized neoantigen vaccine combined with retifanlimab for MMR-p mCRC and mPDAC patients with measurable disease following first-line FOLFIRINOX/FOLFOXIRI (FFX).

NCT ID: NCT01600807 Withdrawn - Clinical trials for Pancreatic Cancer, Metastatic

OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

Start date: n/a
Phase: Phase 1/Phase 2
Study type: Interventional

OSI-906 is a new drug that may stop cancer cells from growing abnormally. This drug has been used in other research studies and information from those suggests that OSI-906 may help block cell receptors involved in tumor growth. Gemcitabine and erlotinib are used as standard treatment for pancreatic cancer. In this research study, the investigators are looking for the highest dose of OSI-906 that can be given safely in combination with gemcitabine and erlotinib. This dose will then be given together with gemcitabine and erlotinib to a further group of patients with pancreatic cancer.